The global robotic biopsy devices market is estimated to be USD 0.486 billion in 2024 and is expected to reach USD 1.99 billion by 2035, with a CAGR of 13.67% during the forecast period 2025-2035. The rising prevalence of cancer and chronic diseases, advances in robotic and imaging technologies, growing demand for minimally invasive procedures, supporting government policies and reimbursement schemes, and rising demand in emerging markets will all fuel market expansion.
The application of NaoTrac displays cutting-edge advances in autonomous robotic navigation, demonstrating how such improvements improve precision and safety in neurosurgery procedures. For instance, in November 2024, Bolivia celebrated a watershed milestone in neurosurgery when two successful brain tumor biopsy procedures were performed at Hospital Arcoiris using NaoTrac, the world's first autonomous surgical navigation robot.
By product, the instrument & accessories segment accounted for the highest revenue-grossing segment in the global robotic biopsy devices market in 2024 owing to the increasing utilization of consumable and reusable components required for each procedure, driven by the rising volume of robotic-assisted biopsy surgeries globally. For instance, in June 2024, RevelAi Health and Zimmer Biomet announced a multi-year cooperation to co-market generative artificial intelligence (AI) products aimed at improving value-based orthopedic care and advancing health equity. As part of this agreement, Zimmer Biomet plans to commercialize RevelAi Health's patient care management platform, which includes a dashboard for care teams and other upcoming products. This cooperation demonstrates both firms' commitment to leveraging AI technology to promote patient engagement and optimize clinical workflows, thereby addressing gaps in healthcare access and outcomes. Additionally, the system segment is predicted to grow at the fastest CAGR during the forecast period owing to the continuous advancements in robotic and imaging technologies, including AI integration and enhanced automation, which improve diagnostic precision and efficiency.
By application, the lung biopsy segment accounted for the highest revenue-grossing segment in the global robotic biopsy devices market in 2024 owing to the rising prevalence of lung cancer and the increasing demand for minimally invasive diagnostic techniques in thoracic oncology. For instance, Brain Navi Biotechnology's flagship autonomous surgical navigation robot, NaoTrac, will be the main attraction at MEDICA 2024, the largest medical trade show in the world, which will be hosted in Düsseldorf, Germany, from November 11-14, in October 2024. Through its cutting-edge machine vision technology, NaoTrac is poised to transform neurosurgery by improving navigation accuracy and supporting neurosurgeons during intricate procedures. Visitors can visit Brain Navi at Hall 16, Booth D12, to get a firsthand look of this game-changing technology. Additionally, the prostate biopsy segment is predicted to grow at the fastest CAGR during the forecast period owing to its increasing adoption in the early detection of prostate cancer, supported by the growing preference for precision medicine and advancements in MRI-guided robotic systems.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global robotic biopsy devices market in 2024 owing to the availability of advanced infrastructure, trained professionals, and a high patient volume requiring complex diagnostic procedures. For instance, in March 2024, "Current State of Intra-/Interobserver Accuracy and Reproducibility in Tissue Biopsy Grossing and Comparison to an Automated Vision System" - Poster #198, a poster presentation at the United States and Canada Association of Pathologists Annual (USCAP) meeting, FormaPath is pleased to announce nToto, a new automated tissue visualization system (ATVS) created in partnership with the Advanced Diagnostics Laboratory at Mayo Clinic. Additionally, the outpatient facilities segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for cost-effective and convenient diagnostic solutions, driven by the trend toward decentralized healthcare and shorter recovery times in outpatient settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of cancer, widespread adoption of advanced robotic technologies, significant healthcare expenditure, and the presence of key market players driving innovation and availability of robotic biopsy devices. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly improving healthcare infrastructure, increasing awareness of early cancer diagnosis, growing investments in advanced medical technologies, and the rising prevalence of cancer in densely populated countries such as China and India. For instance, Insight Medbotics, a medical technology business that combines the precision of robots with the accuracy of MRI, is happy to announce two nominations to its Clinical Advisory Board in July 2024.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
The application of NaoTrac displays cutting-edge advances in autonomous robotic navigation, demonstrating how such improvements improve precision and safety in neurosurgery procedures. For instance, in November 2024, Bolivia celebrated a watershed milestone in neurosurgery when two successful brain tumor biopsy procedures were performed at Hospital Arcoiris using NaoTrac, the world's first autonomous surgical navigation robot.
By product, the instrument & accessories segment accounted for the highest revenue-grossing segment in the global robotic biopsy devices market in 2024 owing to the increasing utilization of consumable and reusable components required for each procedure, driven by the rising volume of robotic-assisted biopsy surgeries globally. For instance, in June 2024, RevelAi Health and Zimmer Biomet announced a multi-year cooperation to co-market generative artificial intelligence (AI) products aimed at improving value-based orthopedic care and advancing health equity. As part of this agreement, Zimmer Biomet plans to commercialize RevelAi Health's patient care management platform, which includes a dashboard for care teams and other upcoming products. This cooperation demonstrates both firms' commitment to leveraging AI technology to promote patient engagement and optimize clinical workflows, thereby addressing gaps in healthcare access and outcomes. Additionally, the system segment is predicted to grow at the fastest CAGR during the forecast period owing to the continuous advancements in robotic and imaging technologies, including AI integration and enhanced automation, which improve diagnostic precision and efficiency.
By application, the lung biopsy segment accounted for the highest revenue-grossing segment in the global robotic biopsy devices market in 2024 owing to the rising prevalence of lung cancer and the increasing demand for minimally invasive diagnostic techniques in thoracic oncology. For instance, Brain Navi Biotechnology's flagship autonomous surgical navigation robot, NaoTrac, will be the main attraction at MEDICA 2024, the largest medical trade show in the world, which will be hosted in Düsseldorf, Germany, from November 11-14, in October 2024. Through its cutting-edge machine vision technology, NaoTrac is poised to transform neurosurgery by improving navigation accuracy and supporting neurosurgeons during intricate procedures. Visitors can visit Brain Navi at Hall 16, Booth D12, to get a firsthand look of this game-changing technology. Additionally, the prostate biopsy segment is predicted to grow at the fastest CAGR during the forecast period owing to its increasing adoption in the early detection of prostate cancer, supported by the growing preference for precision medicine and advancements in MRI-guided robotic systems.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global robotic biopsy devices market in 2024 owing to the availability of advanced infrastructure, trained professionals, and a high patient volume requiring complex diagnostic procedures. For instance, in March 2024, "Current State of Intra-/Interobserver Accuracy and Reproducibility in Tissue Biopsy Grossing and Comparison to an Automated Vision System" - Poster #198, a poster presentation at the United States and Canada Association of Pathologists Annual (USCAP) meeting, FormaPath is pleased to announce nToto, a new automated tissue visualization system (ATVS) created in partnership with the Advanced Diagnostics Laboratory at Mayo Clinic. Additionally, the outpatient facilities segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for cost-effective and convenient diagnostic solutions, driven by the trend toward decentralized healthcare and shorter recovery times in outpatient settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of cancer, widespread adoption of advanced robotic technologies, significant healthcare expenditure, and the presence of key market players driving innovation and availability of robotic biopsy devices. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly improving healthcare infrastructure, increasing awareness of early cancer diagnosis, growing investments in advanced medical technologies, and the rising prevalence of cancer in densely populated countries such as China and India. For instance, Insight Medbotics, a medical technology business that combines the precision of robots with the accuracy of MRI, is happy to announce two nominations to its Clinical Advisory Board in July 2024.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Product, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Robotic Biopsy Devices Market Report 2024 - 2035
Robotic Biopsy Devices Market Analysis & Forecast by Product 2024 - 2035 (Revenue USD Bn)
- System
- Instrument & Accessories
Robotic Biopsy Devices Market Analysis & Forecast by Application 2024 - 2035 (Revenue USD Bn)
- Lung Biopsy
- Brain Biopsy
- Prostate Biopsy
- Other Biopsies
Robotic Biopsy Devices Market Analysis & Forecast by End-User 2024 - 2035 (Revenue USD Bn)
- Hospitals
- Outpatient Facilities
- Others
Robotic Biopsy Devices Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Robotic Biopsy Devices Market: Product Estimates & Trend Analysis
8. Robotic Biopsy Devices Market: Application Estimates & Trend Analysis
9. Robotic Biopsy Devices Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Robotic Biopsy Devices Market
12. Europe Global Robotic Biopsy Devices Market
13. Asia Pacific Global Robotic Biopsy Devices Market
14. Latin America Global Robotic Biopsy Devices Market
15. MEA Global Robotic Biopsy Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Medtronic plc
- Abbott Laboratories
- Johnson & Johnson (Cordis Corporation)
- Terumo Corporation
- Smith & Nephew
- Stryker Corporation
- B. Braun Melsungen AG
- ConMed Corporation
- Cook Medical
- Philips Healthcare
- Huaian Aohong Medical Technology Co., Ltd.
- Medi-Tech International
- Cardinal Health, Inc.
- Optimed Medizinische Instrumente GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.49 Billion |
| Forecasted Market Value ( USD | $ 1.99 Billion |
| Compound Annual Growth Rate | 13.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
